StockData
GE HealthCare Technologies Inc. logo

GE HealthCare Technologies Inc. (GEHC) stock

GEHCNasdaqX-Ray Apparatus & Tubes & Related Irradiation ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 28, 2026Score 14/308% below fair value
$76.57+0.15 (+0.20%)

Close on Oct 30, 2026Market cap $34.59BP/E 17.6Yield 0.18%

Earnings

GE HealthCare Technologies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 3, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$5.50B
+7.8% on a year earlier
Adjusted EPS*, Q3 FY2026
$1.34
$1.07 a year earlier
Latest guidance
Raised
Oct 28, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of GE HealthCare Technologies's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 3, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026before the open$5.50B+7.8%$1.36$1.34Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026before the open$5.30B+6.0%$1.24$1.13Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026before the open$5.10B+6.3%$0.85$0.99Release
Q4 FY2025ended Dec 31, 2025Feb 4, 2026before the open$5.70B+7.5%$1.29$1.44Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025before the open$5.10B+4.1%$0.98$1.07Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025before the open$5.00B+4.2%$1.06$1.06Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025before the open$4.80B+4.3%$1.23$1.01Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025before the open$5.30B+1.9%$1.57$1.45Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$4.90B+2.1%$1.02$1.14Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024before the open$4.80B0.0%$0.93$1.00Release
Q1 FY2024ended Mar 31, 2024Apr 30, 2024before the open$4.60B-2.1%$0.81$0.90Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

GE HealthCare Technologies's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Organic revenue growth*non-GAAPFY2026+3% – +4%+3% – +4%ReaffirmedApr 29, 2026
Organic Revenue Growth*non-GAAPFY2026+4%+3% – +4%RaisedOct 28, 2026
Adjusted EBIT margin*non-GAAPFY202615.4% – 15.7%15.8% – 16.1%LoweredApr 29, 2026
Adjusted EBIT Margin*non-GAAPFY202615.5% – 15.7%15.4% – 15.7%RaisedOct 28, 2026
Adjusted EPS*non-GAAPFY2026$4.95 – $5.05$4.80 – $5.00RaisedOct 28, 2026
Adjusted EPS*non-GAAPFY2026$4.80 – $5.00$4.95 – $5.15LoweredApr 29, 2026
Free cash flow*non-GAAPFY2026$1.60B$1.70BLoweredApr 29, 2026
Free Cash Flow*non-GAAPFY2026$1.60B$1.60BReaffirmedOct 28, 2026
Adjusted effective tax rate (ETR)*non-GAAPFY202620% – 21%–NewJul 29, 2026
Adjusted effective tax rate (ETR)*non-GAAPFY202620% – 21%20% – 21%ReaffirmedApr 29, 2026
Adjusted ETR*non-GAAPFY202620% – 21%–ReaffirmedOct 28, 2026

Guidance vs results

The last range GE HealthCare Technologies gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted EPS*$4.51 – $4.63$4.58Σ4QWithin range

Guidance history

Every forecast GE HealthCare Technologies put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026Adjusted EPS*FY2026$4.95 – $5.05Raised
Oct 28, 2026Free Cash Flow*FY2026$1.60BReaffirmed
Oct 28, 2026Adjusted EBIT Margin*FY202615.5% – 15.7%Raised
Oct 28, 2026Adjusted ETR*FY202620% – 21%Reaffirmed
Oct 28, 2026Organic Revenue Growth*FY2026+4%Raised
Jul 29, 2026Adjusted EPS*FY2026$4.80 – $5.00New
Jul 29, 2026Free cash flow*FY2026$1.60BNew
Jul 29, 2026Adjusted EBIT margin*FY202615.4% – 15.7%New
Jul 29, 2026Adjusted effective tax rate (ETR)*FY202620% – 21%New
Jul 29, 2026Organic revenue growth*FY2026+3% – +4%New
Apr 29, 2026Adjusted EPS*FY2026$4.80 – $5.00Lowered
Apr 29, 2026Free cash flow*FY2026$1.60BLowered
Apr 29, 2026Adjusted EBIT margin*FY202615.4% – 15.7%Lowered
Apr 29, 2026Adjusted effective tax rate (ETR)*FY202620% – 21%Reaffirmed
Apr 29, 2026Organic revenue growth*FY2026+3% – +4%Reaffirmed
Feb 4, 2026Adjusted EPS*FY2026$4.95 – $5.15New
Feb 4, 2026Free cash flow*FY2026$1.70BNew
Feb 4, 2026Adjusted EBIT margin*FY202615.8% – 16.1%New
Feb 4, 2026Adjusted effective tax rate (ETR)*FY202620% – 21%New
Feb 4, 2026Organic revenue growth*FY2026+3% – +4%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases GE HealthCare Technologies filed with the SEC as exhibits to Form 8-K or 6-K

  1. GE HealthCare reports third quarter 2026 financial results
    Results
  2. GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors
    Update
  3. Recast Unaudited Historical Financial Information Reflecting the Company’s New Reportable Segment Structure
    Update
  4. GE HealthCare reports second quarter 2026 financial results
    Results
  5. GE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum
    Results
  6. GE HealthCare reports first quarter 2026 financial results
    Results
  7. GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors
    Update
  8. GE HealthCare reports fourth quarter and full year 2025 financial results
    Results
  9. GE HealthCare reports third quarter 2025 financial results
    Results
  10. GE HealthCare reports second quarter 2025 financial results
    Results
  11. GE HealthCare reports first quarter 2025 financial results
    Results
  12. GE HealthCare reports fourth quarter and full year 2024 financial results
    Results
  13. GE HealthCare hosts 2024 Investor Day: focus on innovation to deliver precision care and drive growth
    Update
  14. Prices Secondary Offering of 13,281,302 Shares
    News
  15. Recast Unaudited Historical Financial Information Reflecting the Company’s New Reportable Segment Structure
    Update